Suzhou CStone Pharma and US-based EQRx reported their partnered PD-(L)1 antibody increased median progression-free survival from 5.8 months to 9.0 months in Stage III NSCLC patients. The data was from a China Phase III trial among previously treated NSCLC patients. In late 2020, CStone out-licensed ex-China rights for its PD-(L)1 and PD-1 candidates to EQRx in a $1.3 billion deal ($150 million upfront). CStone sold C hina c ommercialization rights for the candidate to Pfizer in a $480 million agreement. More details... Stock Symbols: (HK: 2616) Share this with colleagues: // //